The Interplay Between Bioactive Sphingolipids in the Psoriatic Skin and the Severity of the Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jul 29

PMID 37511095

Authors

Mateusz Matwiejuk

Hanna Mysliwiec

Bartlomiej Lukaszuk

Marta Lewoc

Hend Malla

Piotr Mysliwiec

Jacek Dadan

Adrian Chabowski

Iwona Flisiak

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a complex chronic immunologically mediated disease that may involve skin, nails, and joints. It is characterized by hyperproliferation, deregulated differentiation, and impaired apoptosis of keratinocytes. Sphingolipids, namely ceramide, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate, are signal molecules that may regulate cell growth, immune reactions, and apoptosis. Fifteen patients with psoriasis and seventeen healthy persons were enrolled in the study. Skin samples were taken from psoriatic lesions and non-lesional areas. Tissue concentration of ceramides, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate was measured by liquid chromatography. We assessed that all levels of ceramides, sphingosine-1-phosphate, sphingosine, sphingomyelin, and sphinganine-1-phosphate were higher in lesioned psoriatic skin than in non-affected skin. The profile of bioactive lipids in the lesional skin of patients with psoriasis differed significantly from non-involved psoriatic skin and skin in healthy subjects.

Citing Articles

Altered metabolic profiles of dermatomyositis with different myositis-specific autoantibodies associated with clinical phenotype.

Wang N, Shang L, Liang Z, Feng M, Wang Y, Gao C Front Immunol. 2024; 15:1429010.

PMID: 39654882 PMC: 11625817. DOI: 10.3389/fimmu.2024.1429010.

Unveiling the Metabolomic Profile of Oily Sensitive Skin: A Non-Invasive Approach.

Zhang J, Wu F, Wang J, Qin Y, Pan Y Int J Mol Sci. 2024; 25(20).

PMID: 39456816 PMC: 11507585. DOI: 10.3390/ijms252011033.

Sphingosine 1-phosphate receptor 2 in keratinocytes plays a key role in reducing inflammation in psoriasis.

Masuda-Kuroki K, Alimohammadi S, Lowry S, Di Nardo A Front Immunol. 2024; 15:1469829.

PMID: 39391307 PMC: 11464331. DOI: 10.3389/fimmu.2024.1469829.

Crosstalk between Serum and Skin Sphingolipids in Psoriasis.

Matwiejuk M, Mysliwiec H, Lukaszuk B, Lewoc M, Malla H, Mysliwiec P Int J Mol Sci. 2023; 24(19).

PMID: 37834321 PMC: 10573408. DOI: 10.3390/ijms241914872.

The Role of Sphingolipids and Sphingosine-1-phosphate-Sphingosine-1-phosphate-receptor Signaling in Psoriasis.

Masuda-Kuroki K, Alimohammadi S, Di Nardo A Cells. 2023; 12(19).

PMID: 37830566 PMC: 10571972. DOI: 10.3390/cells12192352.

References

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

Fernandez-Armenteros J, Gomez-Arbones X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M . Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2018; 33(1):128-135. DOI: 10.1111/jdv.15159. View

Mysliwiec H, Baran A, Harasim-Symbor E, Choromanska B, Mysliwiec P, Milewska A . Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. Arch Dermatol Res. 2016; 309(2):79-86. PMC: 5309277. DOI: 10.1007/s00403-016-1709-9. View

Sorokin A, Domenichiello A, Dey A, Yuan Z, Goyal A, Rose S . Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J Invest Dermatol. 2018; 138(7):1518-1528. PMC: 6121727. DOI: 10.1016/j.jid.2018.02.003. View

DAmbrosio D, Steinmann J, Brossard P, Dingemanse J . Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2014; 37(1):103-9. DOI: 10.3109/08923973.2014.993084. View

Parisi R, Symmons D, Griffiths C, Ashcroft D . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012; 133(2):377-85. DOI: 10.1038/jid.2012.339. View

Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator P, Burcklen M . Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014; 384(9959):2036-45. DOI: 10.1016/S0140-6736(14)60803-5. View

Baranowski M, Zabielski P, Blachnio A, Gorski J . Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol (Oxf). 2007; 192(4):519-29. DOI: 10.1111/j.1748-1716.2007.01755.x. View

Okura I, Kamata M, Asano Y, Mitsui A, Shimizu T, Sato S . Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes. J Dermatol Sci. 2021; 102(2):116-125. DOI: 10.1016/j.jdermsci.2021.04.004. View

10.

Laporte M, Galand P, Fokan D, De Graef C, Heenen M . Apoptosis in established and healing psoriasis. Dermatology. 2000; 200(4):314-6. DOI: 10.1159/000018394. View

11.

Mitra R, Thompson C, Jasty R, Castle V, Nickoloff B . Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol. 1997; 151(5):1321-9. PMC: 1858068. View

12.

Moon S, Kim J, Song E, Shin M, Cho Y, Kim N . Altered levels of sphingosine and sphinganine in psoriatic epidermis. Ann Dermatol. 2013; 25(3):321-6. PMC: 3756197. DOI: 10.5021/ad.2013.25.3.321. View

13.

Kozlowska D, Harasim-Symbor E, Mysliwiec H, Milewska A, Chabowski A, Flisiak I . Lipid profile disturbances may predispose psoriatic patients to liver dysfunction. Postepy Dermatol Alergol. 2021; 38(2):310-318. PMC: 8362751. DOI: 10.5114/ada.2021.106209. View

14.

Moskot M, Bochenska K, Jakobkiewicz-Banecka J, Banecki B, Gabig-Ciminska M . Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders. Int J Mol Sci. 2018; 19(1). PMC: 5796195. DOI: 10.3390/ijms19010247. View

15.

Maceyka M, Harikumar K, Milstien S, Spiegel S . Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2011; 22(1):50-60. PMC: 3253987. DOI: 10.1016/j.tcb.2011.09.003. View

16.

Alessandrini F, Stachowitz S, Ring J, Behrendt H . The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris. J Invest Dermatol. 2001; 116(3):394-400. DOI: 10.1046/j.1523-1747.2001.01283.x. View

17.

Jurakic Toncic R, Jakasa I, Ljubojevic Hadzavdic S, Goorden S, Vlugt K, Stet F . Altered Levels of Sphingosine, Sphinganine and Their Ceramides in Atopic Dermatitis Are Related to Skin Barrier Function, Disease Severity and Local Cytokine Milieu. Int J Mol Sci. 2020; 21(6). PMC: 7139865. DOI: 10.3390/ijms21061958. View

18.

Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A . Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016; 12(12):1299-1308. DOI: 10.1080/1744666X.2016.1201423. View

19.

Yoo H, Lee E, Lee W, Lee Y . Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase. Anal Biochem. 2002; 303(2):167-75. DOI: 10.1006/abio.2002.5579. View

20.

Lee S, Kim S, Kim Y, Kim J, Hong G, Hong J . Genetic Variants Associated with Elevated Plasma Ceramides in Individuals with Metabolic Syndrome. Genes (Basel). 2022; 13(8). PMC: 9407997. DOI: 10.3390/genes13081497. View